Team, We are not buying now. Price is still trading below major descending resistance (R). As long as we are below R, the structure remains under pressure. ✅ What We Are Waiting For We only buy if: Price breaks above the descending resistance (R) A candle closes clearly above it We see strength (no immediate rejection wick) Ideally: a small pullback that holds above R No breakout = no trade. 🟢 Entry Plan (After Confirmation) Once price: Breaks above R Retests and holds

Current Price: 122.26 (Analysis was generated on Monday Morning) Direction: LONG Confidence level: 64%(Price is holding near highs with strong technical structure and supportive healthcare news, but short-term social volume is limited, keeping confidence moderate.) Targets Target 1: 124.50 Target 2: 126.00 Stop Levels Stop 1: 120.50 Stop 2: 119.20 Key Insights: Here’s what’s driving this setup. MRK is trading just below its 52-week high near $123.33 after a strong multi-month advance. Several traders I follow are focused on the stock’s ability to hold above the $120–$121 zone, which has repeatedly acted as a buy area. As long as price stays above that band, dips continue to get absorbed quickly, which tells me buyers are active. What’s interesting is the character of the move. This isn’t a fast, speculative spike. It’s a steady grind higher with low beta, rising moving averages, and improving relative strength versus the broader market. That kind of action usually attracts longer-horizon capital, which helps limit downside even when momentum cools. Recent Performance: Over the last four weeks, MRK is up roughly 10%, and it’s gained more than 35% over the past year. The stock has consistently made higher lows since the November breakout and is now consolidating tightly near the top of its range. You can see the pressure building — volatility is compressed, and price is coiling just under resistance. Expert Analysis: Several professional traders pointed out that MRK is trading well above its 50-day and 200-day averages, with RSI hovering in the high-60s. That’s strong, but not stretched. The key technical tell for me is how shallow the pullbacks have been. Every dip toward $121 has been met with buying, suggesting institutions are defending their positions rather than distributing. From a weekly trading perspective, a clean push through $123.50 opens the door to the $124.50–$126 area fairly quickly. That’s why I’m setting relatively tight but realistic upside targets for this week. News Impact: The news flow continues to support the long case. Recent FDA and EU approvals tied to Keytruda, along with ongoing oncology pipeline updates, keep Merck in focus as a high-quality defensive growth name. Add in steady dividend demand and healthcare sector rotation, and the backdrop remains favorable rather than fragile. Trading Recommendation: Putting it all together, I’m staying LONG on MRK this week. I like entries on minor pullbacks above $121 with upside toward $124.50 first, then $126 if momentum builds. Risk is clearly defined below $120.50, and I’d step aside if that level fails. This isn’t an aggressive momentum chase — it’s a disciplined trend-following long while the structure remains intact.

MRK - Stock flagging on the daily time frame holding just below $112 resistance level. looking for a breakout move here above $112 for a move towards $115 and $120. Stock is strong at the indicator level.

We buy MERCK shares with the main support of 97 and the target of 157 with a growth of 37 to 57 percent.

Conservative Trade + short impulse + 1/2 correction + BUI test level (exhaustion volume?) + weak approach + biggest volume Ut? + weak test + first bearish bar close entry Calculated affordable virtual stop (bought puts) 1 to 2 R/R take profit 1D Trend "+ short impulse + short volume distribution + neutral zone 2" 1M Trend "+ short impulse + 1/2 correction + resisting bar level + resistance level - strong approach from far + volumed manipulation bar" 1Y CounterTrend "+ long impulse + 1/2 correction"

We enter Wave 5 in the demand zone. NYSE:MRK Wave 4 done We have two profit-taking zones. Follow proper risk and money management.

Merck & Co. (NYSE: NYSE:MRK ) traded lower at $101.53 after receiving conditional FDA approval for two new cattle antiparasitic treatments—Exzolt Cattle-CA1 and Dectomax-CA1. The approvals target rising cases of New World screwworm larvae and fever ticks, two livestock threats that the FDA says could drive hundreds of millions in economic losses. The muted stock reaction reflects broader market caution rather than concern over Merck’s fundamentals. Exzolt Cattle-CA1 is a pour-on solution designed to disrupt parasite growth, while Dectomax-CA1 uses the same active ingredient as fully approved Dectomax, allowing regulators to clear the drug without new safety or manufacturing submissions. The updated formula offers 21 days of reinfestation protection and maintains the same 35-day withdrawal period for treated cattle. The FDA highlighted the urgency of getting these solutions to producers as livestock risks rise heading into 2026. Despite the regulatory win, Merck continues to underperform major indices. The stock is up just 5% YTD versus the S&P 500’s 16.57%, and the three-year return of 0.91% trails the index’s 68.38%. Still, Merck’s animal health segment remains an important revenue pillar and positions the company competitively as agricultural threats increase. Technical Analysis The weekly chart shows NYSE:MRK rallying strongly from long-term trendline support near $72–$75, reclaiming the $95 level and tapping into a major supply/rejection zone around $102. Price reacted sharply from that area, confirming it as resistance. A clean breakout above $102 could open a path toward $134, where the next structural high sits. If sellers remain active, support lies at $95, with deeper structure at $72.

Merck (NYSE: NYSE:MRK ) has secured a major regulatory milestone after the European Commission approved a new subcutaneous version of Keytruda, the company’s flagship cancer therapy. This marks a significant expansion for one of the world’s best-selling immunotherapy drugs, previously only administered intravenously. The new formulation allows injections under the skin, giving patients faster, more convenient access to treatment while reducing strain on hospital infusion facilities. The approval applies to all adult indications for which Keytruda is already authorized in the European Union. Keytruda works by activating the body’s immune system to identify and attack cancer cells, and it remains a cornerstone therapy across multiple cancer types. Merck reported more than $23.3 billion in Keytruda sales during the first nine months of the year, underscoring the drug’s central role in the company’s revenue base. The new delivery method may further strengthen market demand, especially in regions prioritizing efficiency and patient comfort. From a technical standpoint, Merck’s stock continues to trade in a bullish structure. Price action remains firmly above a long-standing ascending support trendline that has held since 2019. As long as this structure remains intact, the next major long-term upside target sits at the $134 level, a zone supported by higher-timeframe momentum. A temporary pullback is possible, and any retracement could provide a retest of the ascending support before buyers attempt another continuation. Overall, Merck’s regulatory win adds fundamental strength to an already constructive technical outlook. With Keytruda’s expanded accessibility and consistent revenue performance, long-term sentiment appears supportive. Bulls will want price to stay above the structural trendline to maintain the pathway toward the $134 target.

🔹 في هذا التحليل الفني لسهم Merck & Co (MRK)، نلاحظ أن السهم كان يتحرك في قناة هابطة منذ فترة طويلة، لكنه مؤخراً نجح في كسر الترند الهابط والخروج من القناة، وهي إشارة فنية مهمة لاحتمال انعكاس الاتجاه إلى صاعد أو على الأقل حركة أفقية. 🔹 القيعان بدأت تتصاعد بشكل واضح بينما القمم متقاربة نسبياً، مما يشير إلى بناء زخم شرائي قد يدفع السهم لاختبار مناطق مقاومة عليا.   🔸 حالياً يواجه السهم مقاومة يومية حول 95.36، وإذا تم اختراقها بثبات، فقد يتجه نحو المقاومة الأسبوعية المهمة عند 100.92.   🔹 الدعم الأقرب حالياً عند 90.27، أما الدعم الشهري الرئيسي فيقع حول مستوى 76.84، والذي يُعتبر خط الدفاع الأهم في حال أي تصحيح. 🔺 النموذج الفني الظاهر قد يكون مثلثاً صاعداً، وهو غالباً نموذج استمراري، لكن في هذا السياق وبعد اتجاه هابط، قد يُفسر كنموذج انعكاسي يشير إلى تحوّل محتمل في الاتجاه. 🎯 خلاصة: السهم يظهر إشارات إيجابية فنية ويستحق المتابعة، خاصةً في حال تأكيد اختراق منطقة 95.36، والتي قد تكون بداية انطلاقة جديدة نحو مستويات أعلى. 📝 Article Description (English): 🔹 This is a technical analysis of Merck & Co. (MRK) stock on the daily timeframe. The stock had been moving within a well-defined downward channel for an extended period, but it has recently broken out of this bearish structure — a key technical signal suggesting a potential trend reversal or at least a transition to sideways movement. 🔹 We can observe higher lows forming while the highs remain relatively flat, indicating the presence of bullish accumulation and a possible ascending triangle structure. 🔸 The price is currently approaching daily resistance around 95.36. A confirmed breakout above this level may open the door toward the key weekly resistance at 100.92. 🔹 The nearest support is at 90.27, while the major monthly support lies at 76.84 — an important level to watch in case of any corrective pullbacks. 🔺 The price pattern resembles an ascending triangle, which is typically a continuation pattern, but in this post-downtrend context, it may signal a reversal setup toward the upside. 🎯 Summary: MRK is showing promising technical signs. A solid breakout above 95.36 could be the beginning of a bullish continuation toward higher levels. Keep it on your watchlist.

After a year of falling prices, MRK looks ready to stage a recovery. The stock is now testing the upper range of its consolidation zone — a potential breakout could open the path back toward previous highs. With strong fundamentals and stellar earnings this year, I’ll be watching closely for a confirmed breakout before riding the trend upward.